Last ¥375.00 JPY
Change Today -1.00 / -0.27%
Volume 1.8M
4563 On Other Exchanges
As of 1:00 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

anges mg inc (4563) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/10/14 - ¥635.87
52 Week Low
10/16/14 - ¥232.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ANGES MG INC (4563)

Related News

No related news articles were found.

anges mg inc (4563) Related Businessweek News

No Related Businessweek News Found

anges mg inc (4563) Details

AnGes MG, Inc., a biopharmaceutical company, is engaged in the research and development, and practical application of genetic medicines. The company is primarily developing Hepatocy growth factor (HGF) genetic medicine, which improves blood circulation by regenerating blood vessels. Its products pipeline includes Collategene for the treatment of peripheral arterial diseases, ischemic heart diseases, Parkinson’s disease, and lymphedema; NFkB decoy oligonucleotide for the treatment of atopic dermatitis and disc degeneration; NFkB decoy oligonucleotide coated PTA balloon catheter for the prevention of vascular restenosis; and CUREPEPTIN functional peptides for the treatment of wounds. The company also provides Naglazyme for the treatment of mucopolysaccharidosis; and CIN therapeutic vaccine for cervical cancer. It has strategic alliances with Daiichi Sankyo Company, Limited for the development of HGF genetic medicine in the fields of peripheral arterial disease and Ischemic heart disease; with Vical, Inc. for the development of Allovectin; and with BioLeaders Corporation for the development of therapeutic vaccine for cervical intraepithelial neoplasia. The company was formerly known as MedGene Bioscience Co., Ltd. and changed its name to AnGes MG, Inc. in October 2001. AnGes MG, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.

38 Employees
Last Reported Date: 03/31/14
Founded in 1999

anges mg inc (4563) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

anges mg inc (4563) Key Developments

AnGes MG, Inc. - Shareholder/Analyst Call

AnGes MG, Inc. - Shareholder/Analyst Call

AnGes MG, Inc. Announces Unaudited Consolidated Earnings Results for the Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Year Ending December 31, 2014

AnGes MG, Inc. announced unaudited consolidated earnings results for the nine months ended September 30, 2014. For the period, the company reported net sales of goods of JPY 221,785,000 against JPY 186,916,000 a year ago. Total business revenues were JPY 281,857,000 against JPY 391,349,000 a year ago. Loss before income taxes and minority interests was JPY 2,083,439,000 against JPY 965,064,000 a year ago. Net loss was JPY 2,090,632,000 or JPY 63.45 per share against JPY 971,794,000 or JPY 32.78 per share a year ago. For the year ending December 31, 2014, the company expects revenues to be in the range of JPY 750 million to JPY 850 million, operating loss to be in the range of JPY 2,600 million to JPY 2,400 million, ordinary loss to be in the range of JPY 2,600 million to JPY 2,400 million and net loss to be in the range JPY 2,600 million or JPY 68.17 per share to JPY 2,400 million or JPY 62.93 per share.

AnGes MG, Inc. to Report Q3, 2014 Results on Oct 27, 2014

AnGes MG, Inc. announced that they will report Q3, 2014 results on Oct 27, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4563:JP ¥375.00 JPY -1.00

4563 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4563.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4563 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.9x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 29.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANGES MG INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at